Psoriasis is a chronic inflammatory disease characterised by sharply demarcated
erythematous and scaly skin lesions accompanied by systemic manifestations. Classified by …

Importance Approximately 125 million people worldwide have psoriasis. Patients with
psoriasis experience substantial morbidity and increased rates of inflammatory arthritis …

Research on psoriasis pathogenesis has largely increased knowledge on skin biology in
general. In the past 15 years, breakthroughs in the understanding of the pathogenesis of …

Background Despite the introduction of new monoclonal antibodies and oral therapies for
the treatment of ulcerative colitis, clinical remission rates remain low, underscoring the need …

Importance Recent studies have shown an association between psoriasis and nonalcoholic
fatty liver disease (NAFLD) in US inpatients, but the association is still unclear in the …

Psoriasis is a complex, chronic relapsing and inflammatory skin disorder with a prevalence
of approximately 2% in the general population worldwide. Psoriasis can be triggered by …

Background & Aims Guselkumab, a selective p19 interleukin-23 antagonist, is approved for
the treatment of plaque psoriasis and psoriatic arthritis. This study evaluated the efficacy and …

Background Many patients with psoriatic arthritis have an inadequate response to tumor
necrosis factor (TNF) inhibitors. Guselkumab, a specific inhibitor of interleukin-23 (IL-23) via …

Summary Background The interleukin-23 (IL-23)/T-helper 17 cell pathway is implicated in
psoriatic arthritis pathogenesis. Guselkumab, an IL-23 inhibitor that specifically binds the IL …

Psoriasis is a chronic, immune-mediated, inflammatory disease that is pathogenically driven
by proinflammatory cytokines. This article reviews the immunologic role of interleukin (IL)-17 …